ADMA Biologics Inc is trading 5.3% down now at $7.48 amid renewed focus on earlier short-seller claims and growth-quality concerns.
- Investors are reassessing the stock following allegations of aggressive revenue recognition and channel stuffing raised in a forensic short report.
- Sentiment remains pressured by prior Q1 2026 revenue disappointment versus expectations, which continues to weigh on the stock despite recent positive FDA label expansion news for ASCENIV.